Research Article

Merit of Ginseng in the Treatment of Heart Failure in Type 1-Like Diabetic Rats

Cheng-Chia Tsai,1,2 Paul Chan,3 Li-Jen Chen,4 Chen Kuei Chang,5 Zhongmin Liu,6 and Jia-Wei Lin5

1 Department of Neurosurgery, Mackay Memorial Hospital, Taipei 104, Taiwan
2 Graduate Institute of Injury Prevention and Control, Taipei Medical University, Taipei 110, Taiwan
3 Department of Cardiology, College of Medicine, Wan Fang Hospital, Taipei Medical University, Taipei 116, Taiwan
4 Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan
5 Department of Neurosurgery, College of Medicine, Shuang Ho Hospital, Taipei Medical University, Taipei 110, Taiwan
6 Department of Cardiothoracic Surgery, Shanghai East Hospital, Tongji University, Shanghai, China

Correspondence should be addressed to Zhongmin Liu; zhongmin_liu@sina.com.cn and Jia-Wei Lin; ns246@tmu.edu.tw

Received 16 January 2014; Accepted 6 February 2014; Published 17 March 2014

Academic Editor: Juei-Tang Cheng

Copyright © 2014 Cheng-Chia Tsai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The present study investigated the merit of ginseng in the improvement of heart failure in diabetic rats and the role of peroxisome proliferator-activated receptors δ (PPARδ). We used streptozotocin-induced diabetic rat (STZ-rat) to screen the effects of ginseng on cardiac performance and PPARδ expression. Changes of body weight, water intake, and food intake were compared in three groups of age-matched rats; the normal control (Wistar rats) received vehicle, STZ-rats received vehicle and ginseng-treated STZ-rats. We also determined cardiac performances in addition to blood glucose level in these animals. The protein levels of PPARδ in hearts were identified using Western blotting analysis. In STZ-rats, cardiac performances were decreased but the food intake, water intake, and blood glucose were higher than the vehicle-treated control. After a 7-day treatment of ginseng in STZ-rats, cardiac output was markedly enhanced without changes in diabetic parameters. This treatment with ginseng also increased the PPARδ expression in hearts of STZ-rats. The related signal of cardiac contractility, troponin I phosphorylation, was also raised. Ginseng-induced increasing of cardiac output was reversed by the cotreatment with PPARδ antagonist GSK0660. Thus, we suggest that ginseng could improve heart failure through the increased PPARδ expression in STZ-rats.

1. Introduction

Diabetes ranks among the main risk factors in the development of chronic heart failure (CHF) [1, 2]. Many patients with CHF and hyperglycemic symptoms have accompanying abnormalities including obesity, dyslipidemia, and hypertension that also lead to structural and functional disorders of heart in cardiac dysfunction and CHF [3–6].

Ginseng varieties have been garnering increasing interest recently for their effects on the cardiovascular system [7]. It has been demonstrated that ginseng could prevent cardiac hypertrophy and heart failure through a mechanism likely involving the prevention of calcineurin activation [8] and the latter representing a key factor for myocardial hypertrophy and remodeling [9, 10].

Peroxisome proliferator-activated receptors (PPARs) are introduced as the ligand-activated transcriptional factors to regulate the expression of genes [11]. It has been classified into three subtypes: PPARα, PPARγ, and PPARδ to modulate the gene expressions for various bioactivities [11]. PPARα is expressed in tissues with a high oxidative capacity, such as liver and heart, while PPARγ is observed in limited tissues, primarily the adipose tissue [11, 12]. PPARδ is known to increase lipid catabolism in both adipose and muscles [11], while PPARδ-dependent cardiac function is also identified [13–15]. Deletion of cardiac PPARδ is mentioned to result in
decreased contraction and lowered cardiac output, showing
an incidence of cardiac failure [13].

A marked decrease of PPARδ expression in the hearts of streptozotocin-induced hyperglycemic rats (STZ-rats) [16]
has been shown. It has also been indicated that impaired
relaxation is the prominent cardiac abnormality due to the
depressed troponin function in the hearts of STZ-rats [17, 18].
Thus, cardiomyopathy in STZ-rats is mainly associated with
the reduced PPARδ expression in hearts [16].

It has been documented that cardiac agents, such as
digoxin and dobutamine, can restore the cardiac contractility
in diabetic rats [19–21]. Also, cardiac agent improved cardiac
contraction in STZ-rats is mainly related to the increased
expression of cardiac PPARδ [16]. Thus, in the present study,
we employed STZ-rats to investigate the merits of ginseng
in the restoration of cardiac performance in diabetic rats
showing heart failure.

2. Material and Methods

2.1. Materials. GSK0660 (a specific PPARδ antagonist) was
purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA, USA). Antibodies specific to PPARδ, cardiac troponin
I (TnI), and phospho-troponin I (p-TnI) (Ser 23/24) were
all the products of Cell Signaling Technology (Beverly, MA,
USA).

2.2. Animals. We purchased the male Wistar rats, weighing
from 250 to 280 g, from the Animal Center of National
Cheng Kung University Medical College. All experiments
were performed under the anesthesia with 2% isoflurane
and all efforts were made to minimize suffering. The animal
experiments were performed in accordance with the Guide
for the Care and Use of Laboratory Animals as well as the
guidelines of the Animal Welfare Act.

2.3. Animals and Experimental Protocol. Diabetes was
induced by an intravenous injection of 60 mg/kg strepto-
zotocin (STZ) [1]. Animals were considered to be useful
as the plasma glucose concentration is up to 20 mmol/L
or greater in addition to polyuria and other hyperglycemic
features. The concentration of plasma glucose was measured
by the glucose oxidase method (Quick-Lab, Ames, Miles,
Inc., Elkhart, IN, USA). All studies were carried out 10 weeks
after induction of diabetes in rats showing cardiomyopathy
as described previously [2]. The STZ-rats received ginseng
powder (150 mg/kg/day, orally) for 7 days. Another group
of STZ-rats received same volume of vehicle; saline (0.9%
sodium chloride, orally) was used for comparison, while
the age-matched normal rats received same treatment with
vehicle were taken as normal control. Then, they were
anesthetized for cannulation in the right femoral artery
with polyethylene catheters (PE-50). Mean arterial pressure
(MAP) and heart rate (HR) were then measured in a
polygraph (MP35, BIOPAC, Goleta, Calif) as described in
our previous report [22]. Basically, all rats were kept under
artificial ventilation while the cardiac output (CO) was
calculated from the aortic blood flow, and the stroke volume
(SV) was expressed as CO divided by HR according to our
previous method [22]. After the experiment, hearts were
isolated to rinse with ice-cold phosphate-buffered saline
(PBS) and weighed.

2.4. Treatment of Antagonist. We used GSK0660 (1 mg/kg)
as specific antagonist of PPARδ as described previously [23].
GSK0660 from Tocris bioscience (Bristol, UK) dissolved in
vehicle (Dimethyl sulfoxide, DMSO, 0.1%) was prepared to
the desired dose in each assay. STZ-rats received ginseng
powder (150 mg/kg/day, orally) for 7 days were injected with
antagonist at one hour before the application of ginseng daily.
Then, animals were anesthetized for determination of cardiac
performance as described above.

2.5. Characterization of Hemodynamic dP/dt. We used
hemodynamic dP/dt to measure the cardiac contractility
as described in our previous report [24]. Basically, the pacing
electrode of LV (IX-214; iWorx Systems, Inc., Dover, NH,
USA) was placed in the anterior wall through the superior
vena cava. After femoral artery and venous insertion using
the Seldinger technique [25], pressure transducer was wired
into the heart to monitor the RV, aortic, mean blood,
and LV pressures. Pressure catheters and pacing leads
were connected to the machine devise (iWorx Systems, Inc.,
Dover, NH, USA) to monitor the heart rate and to calculate
hemodynamic signals. Body temperature was kept at 37.5°C
in whole experiment.

2.6. Western Blotting Analysis. We used the ice-cold radioim-
nunoprecipitation assay (RIPA) buffer to extract the protein
from tissue homogenates or cell lysates as described in our
previous method [16]. The protein level was characterized
using Biorad protein assay (Biorad Laboratories, Inc., Her-
cules, CA, USA). After separation of proteins (30 μg) by
SDS/polyacrylamide gel electrophoresis (10% acrylamide gel)
through a Biorad Miniprotein II system, it was transferred to
the expanded polyvinylidene difluoride membranes (Pierce,
Rockford, IL, USA) with a Biorad Trans-Blot system. Then,
the membranes were washed and blocked for 1 h at room
temperature with 5% (w/v) skimmed milk powder according
to our previous method [16]. The primary antibody reactions
were performed following the manufacturer's instructions.
The blots were incubated with goat polyclonal antibody
(1:1000) to bind actin that served as the internal control.
After removal of primary antibody, the washed blots were
incubated with the appropriate peroxidase-conjugated sec-
ondary antibody for 2 h at room temperature. The blots
were then developed using an ECL-Western blotting sys-
tem (Amersham International, Buckinghamshire, UK). Each
immunoblot, including PPARδ (50 kDa), cardiac troponin I
(28 kDa), or phospho-troponin I (28 kDa), was then quanti-
fied by a laser densitometer.

2.7. Statistical Analysis. Results were expressed as mean ±
SE of each group. Statistical analysis was carried out using
ANOVA analysis and Newman-Keuls post hoc analysis.
Statistical significance was set as P < 0.05.
Table 1: Characteristics of normal rats, diabetic rats, and ginseng-treated diabetic rats.

| Parameters                        | Normal rats          | Diabetic rats | Ginseng-treated diabetic rats |
|-----------------------------------|----------------------|---------------|-------------------------------|
| Food intake (g/day)               | 23.8 ± 3.6           | 42.5 ± 8.3**  | 43.6 ± 4.7**                  |
| Water intake (g/day)              | 41.5 ± 6.9           | 176.3 ± 11.9**| 178.2 ± 11.3**                |
| Plasma glucose (mmol/L)           | 5.8 ± 0.7            | 30.4 ± 3.8*** | 31.2 ± 2.8***                 |
| Body weight (g)                   | 386.8 ± 13.5         | 247.6 ± 11.2**| 253.4 ± 14.6**                |
| Systolic blood pressure (mmHg)    | 117.3 ± 3.6          | 84.5 ± 8.2**  | 109.8 ± 4.7zz                 |
| Diastolic blood pressure (mmHg)   | 81.7 ± 5.4           | 51.9 ± 7.2**  | 78.7 ± 7.6zz                  |
| Heart rate (beats/min)            | 374.7 ± 23.2         | 303.4 ± 18.6* | 297.3 ± 14.5zz                |
| Cardiac output (mL/min)           | 24.7 ± 0.5           | 12.4 ± 0.8    | 19.2 ± 0.7                    |

Values were obtained from normal rats, vehicle-treated diabetic rats, and ginseng-treated diabetic rats. All values were presented as mean ± SEM (n = 6 per group). The ginseng-treated group received the ginseng (150 mg/kg/day, orally for 7 days). *P < 0.05, **P < 0.01, and ***P < 0.001 as compared with normal rats. #P < 0.05 and ##P < 0.01 as compared with vehicle-treated diabetic rats.

3. Results

3.1. Effects of Ginseng on Cardiac Abnormalities in Diabetic Rats. Streptozotocin (STZ) induced the characteristic symptoms of diabetes including hyperglycemia, hypoinsulinemia, and decreased body weight gain along with increased food and water intake when compared with age-matched normal rats (Table 1). The systolic pressure, diastolic pressure, and cardiac output in STZ-rats were markedly lower than those in normal rats (Table 1). The reduced systolic pressure and diastolic pressure in STZ-rats were recovered by ginseng after repeated treatments for 7 days (Table 1). The cardiac output in STZ-diabetic rats was also markedly enhanced by ginseng (Table 1). However, the ginseng-treated STZ-rats did not modify the blood glucose (Table 1). Also, ginseng did not influence the mean ratio of heart and body weight in STZ-rats as compared to the age-matched vehicle-treated STZ-rats (Table 1).

3.2. Effect of Ginseng on PPARδ in the Heart of Diabetic Rats. The level of PPARδ protein was significantly reduced in the heart of diabetic rats as compared with the normal rats (Figure 1). However, a marked increase in the expression of PPARδ was observed in the heart from ginseng-treated STZ-rats (Figure 1).

3.3. Level of TnI Phosphorylation Was Restored by Ginseng in Diabetic Rats. Change in TnI phosphorylation has been introduced to produce a profound effect on cardiac contractility and pumping [26] because phosphorylation of TnI increased cross-bridge cycling rate and enhanced the contraction power [26, 27]. The present study showed that the reduced level of TnI phosphorylation in the hearts of STZ-rats was markedly recovered by ginseng treatment (Figure 2).

3.4. The Recovery of Cardiac Output by Ginseng in Diabetic Rats Was Diminished by Blockade of PPARδ Using GSK0660. Phosphorylation of cTnI is known to induce a marked increase in myofilament Ca^{2+} sensitivity and the force of cardiac contraction [28]. Thus, we investigated the cardiac output in STZ rats. The volume of cardiac output was markedly raised in ginseng treated-STZ group. But, as shown in Figure 3, this action of ginseng was inhibited by PPARδ antagonist named GSK0660 at an effective dose mentioned in previous report [23].

3.5. The Recovery of Cardiac Contractility by Ginseng in Diabetic Rats Was Diminished by Blockade of PPARδ Using GSK0660. The dP/dt max was also restored by ginseng after the repeated treatment for 7 days in STZ-rats, as compared with the vehicle-treated STZ-rats. However, as shown in Figure 4(a), this response disappeared in STZ-rats receiving coadministration of GSK0660 at the effective dose described in previous report [29]. Treatment of ginseng did not modify...
the heart rate but produced a slight increase in blood pressure that was also blocked by GSK0660 (Figures 4(b) and 4(c)).

4. Discussion

The present study found that administration of ginseng caused a marked recovery of cardiac output in addition to the lowered cardiac PPARδ expression and troponin I phosphorylation in type 1-like diabetic rats. As shown in Table 1, the reduced cardiac output in diabetic rats was also markedly reversed by this repeated treatment of ginseng (150 mg/kg, orally) for 7 days that showed the most effective period. In anesthetized STZ-rats, cardiac contraction (dP/dt max) was also significantly restored by ginseng and this change was blocked by GSK0660. However, ginseng did not modify the heart beating at this dosing. Thus, to the best of our knowledge, this is the first study to show that ginseng could restore heart failure through an activation of PPARδ in type 1-like diabetic rats.

Multiple actions of ginseng are related to the treated concentrations. It has been indicated that oral administration of ginseng (12 mg/kg a daily for a 2 weeks) showed neuronal protective effect on rat with Parkinson’s disease [30]. Also, rat treated with ginseng (250 or 500 mg/kg) inhibited the myocardial infarction after acute myocardial ischemia reperfusion injury [31] and isoproterenol-induced cardiac injury in rats [32]. Moreover, it was mentioned that ginseng (400 mg/kg) may enhance cardiac performance through an increase in the expression of PPARδ and without altering the heart rate in normal rats [33]. In the present study, the cardiac performance in diabetic rats was also improved by repeated oral intake of ginseng at 150 mg/kg/day for one week and this used dose is markedly lower than used in previous reports for cardiac diseases [7, 8, 32, 34]. Also, this dose is equal to human oral dose about 1452 mg/kg by using the U.S. FDA HED (human equivalent dose) equation for calculation [35–37].

It has been indicated that type 1-like diabetes in STZ-induced animal is characterized by bradycardia and hypotension [38]. In conscious rats, the cardiomyopathy in this kind of animal model for heart failure was expressed by low indices of contractility and relaxation [39]. Actually, we observed the decreased cardiac dp/dt and cardiac output in STZ-induced diabetic rats similar to previous reports [22, 40].

In vivo and in vitro investigations have revealed a number of significant actions of ginsenosides and ginseng extracts in cardioprotection, such as reducing myocardial ischemia-reperfusion induced damage via NO pathway in rats and mice [41], slowing down deterioration of cardiac contractions, preventing the development of arrhythmias [42], and relaxing the muscles of the aorta [43]. Also, it has been documented that ginseng increases cardiac lipid metabolism by enhancement of PPARδ expression and this action of ginseng can be blocked by the specific antagonist GSK0660 [44]. In this study, we found that ginseng could increase PPARδ expression and TnI phosphorylation in the heart of diabetic rats.
Figure 4: Effects of ginseng on cardiac performance in anesthetized rats. The effects of coadministration of ginseng and/or GSK0660 were investigated in the anesthetized STZ-rats. The changes in hemodynamic $dP/dt$ (a), mean blood pressure (MBP) (b), and heart rate (HR) (c) were recorded continuously throughout the whole experiment. All values are presented as mean ± SEM ($n=8$). ***$P<0.001$ as compared to normal rats. ###$P<0.001$ as compared with the ginseng-treated diabetic rats.

It has been established that PPARδ plays an important role in the regulation of cardiac performance [17–19]. In this study, we demonstrated that ginseng increases cardiac contractility without affecting heart rate in STZ-rats. Also, this cardiac tonic action of ginseng was reversed by blockade of PPARδ using antagonist. Furthermore, activation of PPARδ using ginseng may enhance the hemodynamic $dP/dt_{\text{max}}$ in the STZ-rats. Both actions of ginseng were inhibited by GSK0660 at a dose sufficient to block PPARδ [39, 40]. The restoration of cardiac contractility in STZ-rats by ginseng through an activation of PPARδ is then characterized.

The decreased level of TnI phosphorylation was reversed by ginseng in STZ-diabetic rats. Previous study showed an increase of TnI phosphorylation in rats after induction of diabetes for 8 weeks [45]. However, the reduced phosphorylation of TnI was observed in the failing heart of human studies [46]. In the present study, the reduction of TnI phosphorylation may indicate severe contractile defects in the heart of rats after induction of diabetes for 12 weeks or more. Furthermore, the lower TnI phosphorylation was also raised in the heart of STZ-diabetic rats by ginseng. Previous study indicated many phosphorylation sites on cardiac troponin I (cTnI) in physiological and pathophysiological cardiac function [47]. Studies of proteomic analysis on human heart samples taken from end-stage heart failure and rat heart samples demonstrate that Ser23/Ser24 are the major and perhaps the only sites likely to be relevant to control cardiac function [48]. Previous studies have demonstrated that TnI phosphorylation most likely acts through an enhanced off rate during Ca$^{2+}$ exchange with TnC, leading to acceleration of relaxation and an increase in cardiac output [45, 46, 49–51]. It is suggested that the influence of ginseng on increased phosphorylation of TnI
may be mediated through increasing $\text{Ca}^{2+}$ concentrations. However, this view needs more investigations to support in the future.

The inotropic action of ginseng showed cardiac output and cardiac $\frac{dp}{dt}$ was reversed by blockade of PPAR$\delta$ using chemical antagonist named GSK0660 as described previously [23]. In the present study, the increased cardiac output or cardiac $\frac{dp}{dt}$ by ginseng was inhibited in diabetic rats receiving combined treatment with antagonist of PPAR$\delta$. Thus, we conclude that activation of PPAR$\delta$ is involved in the ginseng-induced increase of cardiac contractility known as inotropic action. However, the effects of GSK0660 on changes of downstream signals and cardiac TnI phosphorylation or others shall be investigated in the future.

A change in heart rate is the most serious side effect of cardiac agents [41, 42]. In the present study, we showed that ginseng generated cardiac tonic action in animals without impacting the heart rate. Thus, ginseng can be used as cardiac agent without side effect of arrhythmia.

In cardiac agents, the PPAR$\delta$ agonist (GW0742) enhanced cardiac contractility was higher than that in the dobutamine treated samples. The increase in cardiac output caused by GW0742 was also higher than dobutamine in animals. Also, there is a slight elevation of mean blood pressure with no change of heart rate in rats treated with GW0742. This result is different to the action of dobutamine [24]. Also, the effects of ginseng on STZ rats are similar to the actions of digoxin in STZ rats and both agents restored the expression of PPAR$\delta$ and the cardiac contractility in STZ rats [22]. However, ginseng shows no side effect on heart rate unlike digoxin or other clinical used agents. Thus, application of ginseng to enhance cardiac performance through the activation of PPAR$\delta$ may be a good therapeutic strategy.

5. Conclusion

According to these findings, we suggest that the expression of PPAR$\delta$ restored by ginseng results in cardiac troponin phosphorylation in STZ-rats. Subsequently, the cardiac performance is reversed. Taken together, ginseng restored cardiac contractility through an increase in PPAR$\delta$ expression at the dose that did not modify the heart beating in STZ-rats. Thus, ginseng could be developed as a good cardiac agent without the side effect on heart rate in treatment of diabetic heart failure.

Conflict of Interests

The authors have not disclosed any conflict of interests.

Authors’ Contribution

Cheng-Chia Tsai and Paul Chan equally contributed to the work.

Acknowledgments

The authors thank Yang-Lian Yan and Yi-Zhi Chen for their assistance in our experiments. The present study was supported in part by Grant (TMU102-AE2-1013) from Taipei Medical University, Taipei, Taiwan.

References

[1] W. B. Kannel, M. Hjortland, and W. P. Castelli, “Role of diabetes in congestive heart failure: the Framingham study,” American Journal of Cardiology, vol. 34, no. 1, pp. 29–34, 1974.
[2] W. B. Kannel and D. L. McGee, “Diabetes and cardiovascular disease. The Framingham study,” Journal of the American Medical Association, vol. 241, no. 19, pp. 2035–2038, 1979.
[3] K. Malmberg and L. Ryden, “Myocardial infarction in patients with diabetes mellitus,” European Heart Journal, vol. 9, no. 3, pp. 259–264, 1988.
[4] J. Herlitz, K. Malmberg, B. W. Karlsson, L. Ryden, and A. Hjalmarson, “Mortality and morbidity during a five-year follow-up of diabetics with myocardial infarction,” Acta Medica Scandinavica, vol. 224, no. 1, pp. 31–38, 1988.
[5] I. G. Poornima, P. Parikh, and R. P. Shannon, “Diabetic cardiomyopathy: the search for a unifying hypothesis,” Circulation Research, vol. 98, no. 5, pp. 596–605, 2006.
[6] D. An and B. Rodrigues, “Role of changes in cardiac metabolism in development of diabetic cardiomyopathy,” American Journal of Physiology, vol. 291, no. 4, pp. H1489–H1506, 2006.
[7] M. Karmazyn, M. Moey, and X. T. Gan, “Therapeutic potential of ginseng in the management of cardiovascular disorders,” Drugs, vol. 71, no. 15, pp. 1989–2008, 2011.
[8] J. Guo, X. T. Gan, J. V. Haist et al., “Ginseng inhibits cardiomyocyte hypertrophy and heart failure via nhe-1 inhibition and attenuation of calcineurin activation,” Circulation, vol. 4, no. 1, pp. 79–88, 2011.
[9] N. Frey and E. N. Olson, “Cardiac hypertrophy: the good, the bad, and the ugly,” Annual Review of Physiology, vol. 65, pp. 45–79, 2003.
[10] J. M. Berry, V. Le, D. Rotter et al., “Reversibility of adverse, calcineurin-dependent cardiac remodeling,” Circulation Research, vol. 109, no. 4, pp. 407–417, 2011.
[11] Q. Yang and Y. Li, “Roles of PPARs on regulating myocardial energy and lipid homeostasis,” Journal of Molecular Medicine, vol. 85, no. 7, pp. 697–706, 2007.
[12] I. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990.
[13] L. Cheng, G. Ding, Q. Qin et al., “Cardiomyocyte-restricted peroxisome proliferator-activated receptor$\delta$ deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy,” Nature Medicine, vol. 10, no. 11, pp. 1245–1250, 2004.
[14] L. Cheng, G. Ding, Q. Qin et al., “Peroxisome proliferator-activated receptor$\delta$ activates fatty acid oxidation in cultured neonatal and adult cardiomyocytes,” Biochemical and Biophysical Research Communications, vol. 313, no. 2, pp. 277–286, 2004.
[15] G. D. Barish, V. A. Narkar, and R. M. Evans, “PPAR$\delta$: a dagger in the heart of the metabolic syndrome,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 590–597, 2006.
[16] B.-C. Yu, C.-K. Chang, H.-Y. Ou, K.-C. Cheng, and J.-T. Cheng, “Decrease of peroxisome proliferator-activated receptor delta expression in cardiomyopathy of streptozotocin-induced
diabetic rats,” Cardiovascular Research, vol. 80, no. 1, pp. 78–87, 2008.

[17] F. S. Fein, L. B. Kornstein, and J. E. Strobeck, “Altered myocardial mechanics in diabetic rats,” Circulation Research, vol. 47, no. 6, pp. 922–933, 1980.

[18] F. S. Fein, J. E. Strobeck, and A. Malhotra, “Reversibility of diabetic cardiomyopathy with insulin in rats,” Circulation Research, vol. 49, no. 6, pp. 1251–1261, 1981.

[19] M. T. Chou, S. H. Lo, K. C. Cheng, Y. X. Li, L. J. Chen, and J. T. Cheng, “Activation of β-adrenoceptors by dobutamine may induce a higher expression of peroxisome proliferator-activated receptors δ (PPARδ) in neonatal rat cardiomyocytes,” The Scientific World Journal, vol. 2012, Article ID 248320, 8 pages, 2012.

[20] Z.-C. Chen, B.-C. Yu, L.-J. Chen, K.-C. Cheng, H. J. Lin, and J.-T. Cheng, “Characterization of the mechanisms of the increase in PPARδ expression induced by digoxin in the heart using the H9c2 cell line,” British Journal of Pharmacology, vol. 163, no. 2, pp. 390–398, 2011.

[21] J. Zhao, W. D. Cai, Y. X. Gan et al., “A comparison of HIV infection and related risk factors between money boys and noncommercial men who have sex with men in Shenzhen, China,” Sexually Transmitted Diseases, vol. 39, no. 12, pp. 942–948, 2012.

[22] S. C. Fan, B. C. Yu, Z. C. Chen, L. J. Chen, H. H. Chung, and J. T. Cheng, “The decreased expression of Peroxisome Proliferator-Activated Receptors (PPAR) is reversed by digoxin in the heart of diabetic rats,” Hormone and Metabolic Research, vol. 42, no. 9, pp. 637–642, 2010.

[23] B. G. Shearer, D. J. Steger, J. M. Way et al., “Identification and characterization of a selective peroxisome proliferator-activated receptor β/δ (NRC2) antagonist,” Molecular Endocrinology, vol. 22, no. 2, pp. 523–529, 2008.

[24] Z. C. Chen, K. S. Lee, L. J. Chen, L. Y. Wang, H. S. Niu, and J. T. Cheng, “Cardiac peroxisome proliferator-activated receptor δ (PPARδ) as a new target for increased contractility without altering heart rate,” PLoS ONE, vol. 8, no. 5, Article ID e64229, 2013.

[25] S. I. Seldinger, “Catheter replacement of the needle in percutaneous arteriography: a new technique,” Acta Radiologica, vol. 49, no. 3, pp. 47–52, 2008.

[26] J. Layland, R. J. Solaro, and A. M. Shah, “Regulation of cardiac contractile function by troponin I phosphorylation,” Cardiovascular Research, vol. 66, no. 1, pp. 12–21, 2005.

[27] J. M. Metzger and M. V. Westfall, “Cova lent and noncovalent modification of thin filament action: the essential role of troponin in cardiac muscle regulation,” Circulation Research, vol. 94, no. 2, pp. 146–158, 2004.

[28] T. Kobayashi, L. Jin, and P. P. de Tombe, “Cardiac thin filament regulation,” Pflugers Archiv, vol. 457, no. 1, pp. 37–46, 2008.

[29] I. Paterniti, E. Esposito, E. Mazzon et al., “Evidence for the role of peroxisome proliferator-activated receptor-β/δ in the development of spinal cord injury,” Journal of Pharmacology and Experimental Therapeutics, vol. 333, no. 2, pp. 465–477, 2010.

[30] J. Y. Wang, J. Y. Yang, F. Wang et al., “Neuroprotective effect of pseudoginsenoside-F11 on a rat model of Parkinson’s disease induced by 6-hydroxydopamine,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 152798, 9 pages, 2013.

[31] L. Pei, H. Shaozhen, D. Gengting, C. Tingbo, L. Liang, and Z. Hua, “Effectiveness of Panax ginseng on acute myocardial ischemia reperfusion injury was abolished by flutamide via endogenous testosterone-mediated akt pathway,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 817826, 9 pages, 2013.

[32] K. H. Lim, D. Ko, and J. H. Kim, “Cardioprotective potential of Korean Red Ginseng extract on isoproterenol-induced cardiac injury in rats,” Journal of Ginseng Research, vol. 37, no. 3, pp. 273–282, 2013.

[33] J. W. Lin, Y. G. Cheng, L. J. Chen, H. S. Niu, C. K. Chang, and C. S. Niu, “Ginseng is useful to enhance cardiac contractility in animals,” BioMed Research International, vol. 2014, Article ID 723084, 9 pages, 2014.

[34] H.-X. Li, S.-Y. Han, X. Ma et al., “The saponin of red ginseng protects the cardiac myocytes against ischemic injury in vitro and in vivo,” Phytomedicine, vol. 19, no. 6, pp. 477–483, 2012.

[35] I. Caverio, “10th annual meeting of the Safety Pharmacology Society: an overview,” Expert Opinion on Drug Safety, vol. 10, no. 2, pp. 319–333, 2011.

[36] W. C. Buhles, “Compassionate use: a story of ethics and science in the development of a new drug,” Perspectives in Biology and Medicine, vol. 54, no. 3, pp. 304–315, 2011.

[37] T. Keida, N. Hayashi, and M. Kawashima, “Application of the Food and Drug Administration (FDA) bioequivalence guidance of topical dermatological corticosteroid in yellow-skinned Japanese population: validation study using a chromometer,” Journal of Dermatology, vol. 33, no. 10, pp. 684–691, 2006.

[38] B. D. Schaan, P. D’Alì, C. Y. Maeda et al., “Relationship between cardiovascular dysfunction and hyperglycemia in streptozotocin-induced diabetes in rats,” Brazilian Journal of Medical and Biological Research, vol. 37, no. 12, pp. 1893–1902, 2004.

[39] G. R. Borges, M. de Oliveira, H. C. Salgado, and R. Fazan Jr., “Myocardial performance in conscious streptozotocin diabetic rats,” Cardiovascular Diabetology, vol. 5, article 26, 2006.

[40] Y. Z. Cheng, L. J. Chen, W. J. Lee, M. F. Chen, H. J. Lin, and J. T. Cheng, “Increase of myocardial performance by Rhodiola-ethanol extract in diabetic rats,” Journal of Ethnopharmacology, vol. 144, no. 2, pp. 234–239, 2012.

[41] H. Zhou, S. Z. Hou, P. Luo et al., “Ginseng protects rodent hearts from acute myocardial ischemia-reperfusion injury through GR/ER-activated RISK pathway in an endothelial NOS-dependent mechanism,” Journal of Ethnopharmacology, vol. 135, no. 2, pp. 287–298, 2011.

[42] G. I. Scott, P. B. Colligan, B. H. Ren, and J. Ren, “Ginsenosides Rbl and Re decrease cardiac contraction in adult rat ventricular myocytes: role of nitric oxide,” British Journal of Pharmacology, vol. 134, no. 6, pp. 1159–1165, 2001.

[43] S. Y. Kang, V. B. Schini-Kerth, and N. D. Kim, “Ginsenosides of the protopanaxatriol group cause endothelium-dependent relaxation in the rat aorta,” Life Sciences, vol. 56, no. 19, pp. 1577–1586, 1995.

[44] S. C. Kuo, P. M. Ku, L. J. Chen, H. S. Niu, and J. T. Cheng, “Activation of receptors δ (PPARδ) by agonist (GW0742) may enhance lipid metabolism in heart both in vivo and in vitro,” Hormone and Metabolic Research, vol. 45, no. 12, pp. 880–886, 2013.

[45] X. Liu, N. Takeda, and N. S. Dhalia, “Troponin I phosphorylation in heart homogenate from diabetic rat,” Biochimica et Biophysica Acta, vol. 1316, no. 2, pp. 78–84, 1996.
for the contractile defect in end-stage heart failure,” *Journal of Molecular and Cellular Cardiology*, vol. 42, no. 1, pp. 247–259, 2007.

[47] S. Ayaz-Guner, J. Zhang, L. Li, J. W. Walker, and Y. Ge, “In vivo phosphorylation site mapping in mouse cardiac troponin I by high resolution top-down electron capture dissociation mass spectrometry: Ser22/23 are the only sites basally phosphorylated,” *Biochemistry*, vol. 48, no. 34, pp. 8161–8170, 2009.

[48] G. A. MacGowan, C. Evans, T. C.-C. Hu et al., “Troponin I protein kinase C phosphorylation sites and ventricular function,” *Cardiovascular Research*, vol. 63, no. 2, pp. 245–255, 2004.

[49] C. A. Tate, M. F. Hyek, and G. E. Taffet, “The role of calcium in the energetics of contracting skeletal muscle,” *Sports Medicine*, vol. 12, no. 3, pp. 208–217, 1991.

[50] L. Li, J. Desantiago, G. Chu, E. G. Kranias, and D. M. Bers, “Phosphorylation of phospholamban and troponin I in β-adrenergic-induced acceleration of cardiac relaxation,” *American Journal of Physiology*, vol. 278, no. 3, pp. H769–H779, 2000.

[51] Y. Pi, K. R. Kemnitz, D. Zhang, E. G. Kranias, and J. W. Walker, “Phosphorylation of troponin I controls cardiac twitch dynamics: evidence from phosphorylation site mutants expressed on a troponin I-null background in mice,” *Circulation Research*, vol. 90, no. 6, pp. 649–656, 2002.